Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy

Antiviral Therapy

Volumn 10, Issue 1, 2005, Pages 135-143

  Kovacic, Jason C ^a   Martin, Allison ^b   Carey, Dianne ^b   Wand, Handan ^b   Mallon, Patrick W G ^a,b   Feneley, Michael P ^a   Emery, Sean ^b   Cooper, David A ^a,b   Carr, Andrew ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANABOLIC AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; C PEPTIDE; CD4 ANTIGEN; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GLUCOSE; GLYCERYL TRINITRATE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TESTOSTERONE; TRIACYLGLYCEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTERY DILATATION; ARTICLE; B SCAN; BLOOD PRESSURE; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOREARM BLOOD FLOW; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INFECTION; VIRUS LOAD; AUSTRALIA; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RISK FACTOR; VASODILATATION;

ADULT; ANTI-HIV AGENTS; AUSTRALIA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; RISK FACTORS; THIAZOLIDINEDIONES; VASODILATION;

EID: 18344394640     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17(Suppl 1):S141-S148.
2. Mallon PWG, Cooper DA & Carr A. HIV-associated lipodystrophy. HIV Medicine 2001; 2:166-173.
3. Mallon PWG, Miller J, Cooper DA & Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971-979.
4. Sklar PS & Masur MD. HIV infection and cardiovascular disease - is there really a link? New England Journal of Medicine 2003; 349:2065-2067.
5. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD & Sosman JM. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
6. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R & Mooser V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-705.
7. Maggi P, Serio G, Epifani G, Florentino G, Saracino A, Fico C, Perilli F, Lillo A, Ferraro S, Gargiulo M, Chirianni A, Angarano G, Regina G & Pastore G. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14:F123-F128.
8. Bonnet E, Ruidavets JB, Tuech J, Ferrieres J, Collet X, Fauvel J, Massip P & Perret B. Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. Journal of Clinical Endocrinology & Metabolism 2001; 86:296-302.
9. Behrens GM, Meyer-Olson D, Stoll M & Schmidt RE. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003; 17(Suppl 1):S149-S154.
10. Friedl AC, Attenhofer Jost CH, Schalcher C, Amann FW, Flepp M, Jenni R, Linka A & Weber R. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. AIDS 2000; 14:2790-2792.
11. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR & Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Annals of Internal Medicine 2001; 134:61-71.
12. Sidhu JS, Cowan D & Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. Journal of the American College of Cardiology 2003; 42:1757-1763.
13. Paradisi G, Steinberg HO, Shepard MK, Hook G & Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism 2003; 88:576-580.
14. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitman ML & Taylor SI. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Annals of Internal Medicine 2000; 133:263-274.
15. Walli R, Michl GM, Muhlbayer D, Brinkmann L & Goebel FD. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Research in Experimental Medicine (Berlin) 2000; 199:253-262.
16. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CE, Brebbia JS, Wax MR & McNurlan MA. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. Journal of Acquired Immune Deficiency Syndromes 2002; 31:163-170.
17. Calmy A, Hirschel B, Hans D, Karsegard VL & Meier CA. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS 2003; 17:770-772.
18. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M & Yki-Jarvinen H. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antiviral Therapy 2003; 8:199-207.
19. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S & Cooper DA. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429-438.
20. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK & Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111-1115.
21. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O & Deanfield JE. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. British Heart Journal 1995; 74:247-253.
22. Raitakari OT & Celermajer DS. Flow-mediated dilatation. British Journal of Clinical Pharmacology 2000; 50:397-304.
23. Perneger TV. What's wrong with Bonferroni adjustments. British Medical Journal 1998; 316:1236-1238.
24. Nystrom T, Bratt G & Sjoholm A. Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance. Journal of Internal Medicine 2002; 252:570-574.
25. Doser N, Kubli S, Telenti A, Marzolini C, Chave JP, Feihl F, Buclin T, Pannatier A, Darioli R, Nicod P, Waeber B & Mooser V. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS 2002; 16:1982-1983.
26. Stein JH, Merwood MA, Bellehumeur JL, Aeschlimann SE, Korcarz CE, Underbakke GL, Mays ME & Sosman JM. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. American Heart Journal 2004; 147:713.
27. Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RM & Deanfield JE. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997; 96:3378-3383.
28. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J & Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. Journal of the American College of Cardiology 2002; 39:257-265.
29. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R & Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43:278-284.
30. Nolan JJ, Jones NP, Patwardhan R & Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabetic Medicine 2000; 17:287-294.
31. Bennett SM, Agrawal A, Elasha H, Heise M, Jones NP, Walker M & Wilding JP. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetic Medicine 2004; 21:415-422.
32. Watanabe Y, Sunayama S, Shimada K, Sawano M, Hoshi S, Iwama Y, Mokuno H, Daida H & Yamaguchi H. Troglitazone improves endothelial dysfunction in patients with insulin resistance. Journal of Atherosclerosis & Thrombosis 2000; 7:159-163.
33. Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES & Veves A. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003; 52:173-180.
34. Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS & Ferrannini E. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004; 27:1349-1357.
35. Wang TD, Chen WJ, Lin JW, Chen MF & Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. American Journal of Cardiology 2004; 93:362-365.
36. Yamagishi T, Saito Y, Nakamura T, Takeda S, Kanai H, Sumino H, Kuro-o M, Nabeshima Y, Kurabayashi M & Nagai R. Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. Hypertension Research 2001; 24:705-709.
37. Walker AB, Chattington PD, Buckingham RE & Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48:1448-1453.
38. Tack CJ, Ong MK, Lutterman JA & Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia 1998; 41:569-576.
39. Conklin BS, Fu W, Lin PH, Lumsden AB, Yao Q & Chen C. HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. Cardiovascular Research 2004; 63:168-175.
40. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T & Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. Journal of Biological Chemistry 2002; 277:25863-25866.
41. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y & Walsh K. Obesity, adiponectin and vascular inflammatory disease. Current Opinion in Lipidology 2003; 14:561-566.
42. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD & Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. Journal of the American College of Cardiology 2004; 44:1819-1824.
43. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S & Kadowaki T. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. Journal of Biological Chemistry 2001; 276:41245-41254.
44. Considine RV. Regulation of leptin production. Reviews in Endocrine & Metabolic Disorders 2001; 2:357-363.
45. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG & Saag MS. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. Journal of Acquired Immune Deficiency Syndromes 2002; 31:257-275.